Search results for "Highlights"
Whole, plant-based diet most effective for type 2 diabetes remission, ACLM says
Diet as a primary intervention can achieve remission for many with type 2 diabetes and should focus on plant-based foods with minimal consumption of meat and other animal products, according to a statement from the American College of Lifestyle Medicine (ACLM).
https://diabetes.acponline.org/archives/2022/06/10/3.htm
10 Jun 2022
DPP-4 inhibitors associated with risk of cholecystitis, meta-analysis finds
Patients with type 2 diabetes who were randomized to receive dipeptidyl peptidase-4 (DPP-4) inhibitors had higher rates of gallbladder disease than those who got placebo or nonincretin drugs, but no difference in risk of cholelithiasis or biliary diseases.
https://diabetes.acponline.org/archives/2022/07/08/1.htm
8 Jul 2022
Cystatin C levels associated with risk of sight-threatening diabetic retinopathy
The biomarker may be useful for predicting this condition, especially in areas that don't have access to retinal imaging, according to an analysis of ophthalmology patients in the United Kingdom and India.
https://diabetes.acponline.org/archives/2022/05/13/3.htm
13 May 2022
HbA1c, CGM data significantly differed in patients with kidney disease
Patients with diabetes and chronic kidney disease often had discordance between their HbA1c levels and continuous glucose monitoring (CGM) data, with the HbA1c being significantly higher on average than the CGM-calculated glucose, a French study found.
https://diabetes.acponline.org/archives/2022/05/13/2.htm
13 May 2022
Spotlight on efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists
One recent study compared sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to each other, a meta-analysis tried to quantify their benefits compared to placebo, and a third study looked at their effects relative to insulin.
https://diabetes.acponline.org/archives/2022/05/13/5.htm
13 May 2022
Statins compared for non-HDL cholesterol levels in patients with diabetes
Moderate- and high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin were most effective at moderately reducing levels of non-high-density lipoprotein (HDL) cholesterol, a systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2022/04/08/1.htm
8 Apr 2022
Manufacturer's trials find positive results for combo drug for type 2 diabetes
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
https://diabetes.acponline.org/archives/2021/07/09/3.htm
9 Jul 2021
GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases
A systematic review and meta-analysis of 76 randomized trials found that use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss.
https://diabetes.acponline.org/archives/2022/04/08/2.htm
8 Apr 2022
Unrecognized risk factors for severe hypoglycemia outlined in insulin-treated type 2 diabetes
An industry-funded case-control study of data from a U.S. administrative claims database found that pregnancy, alcohol misuse, short or rapid-acting insulin, and smoking, among other conditions and medications, were independently associated with increased risk.
https://diabetes.acponline.org/archives/2022/04/08/3.htm
8 Apr 2022
Recent articles address federal diabetes programs, type 1 diabetes care
The National Clinical Care Commission made 39 recommendations for improving federal diabetes programs, and the latest In the Clinic article offered advice on diagnosing and treating type 1 diabetes.
https://diabetes.acponline.org/archives/2022/03/11/6.htm
11 Mar 2022